Program
IIV-HD + NVXC19 combination
Also written as “IIV-HD”, “IIV-HD + rC19 (dose 1)” and “IIV-HD + rC19 (dose 2)”.
Its studies are mostly in Influenza, Human, led by Sanofi.
Furthest: phase 3, since Oct 15, 20262 company-led studies, 1 open or runningNext primary completion: Dec 28, 2027 (phase 3)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Sanofi | 21 open or running | phase 3since Oct 15, 2026 | Nov 14, 2024 | Dec 28, 2027phase 3 · NCT07890454 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Nov 14, 2024First study: phase 2 study in Influenza, HumanFirst studyNCT06695117 · 980 enrolled · United States
- Oct 15, 2026Phase 3 study in Influenza, HumanPhase 3 reachedNCT07890454 · 6,000 planned · Poland
Ahead
- Dec 28, 2027Primary completion: phase 3 study in Influenza, HumanNCT07890454
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 2 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07890454Influenza, Human · Poland | 3 | Recruiting | Dec 28, 2027 | 6,000 |
| NCT06695117Influenza, Human · United States | 2 | Completed | Apr 16, 2026 | 980 |
How it is read
Names in the registry
- “IIV-HD + NVXC19 combination”, 1 entry
- “IIV-HD”, 1 entry
- “IIV-HD + rC19 (dose 1)”, 1 entry
- “IIV-HD + rC19 (dose 2)”, 1 entry
- “IIV-HD + rC19 (dose 3)”, 1 entry
Conditions, from the studies’ own filings
- Influenza, Human, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.